
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity is a leading life sciences and diagnostics company with a strong focus on pre-clinical work and potential for long-term growth in AI-enabled drug discovery. While the divestiture in 2023 is expected to improve profitability and organic growth, challenges in the industry may impact these goals. The acquisition of EUROIMMUN has strengthened Revvity's presence in the US and the company's performance in the Reproductive Health segment is strong. However, competition and doubts about the sustainability of growth in Immunodiagnostics may pose potential risks for the company's future.
Bears say
Revvity is facing several challenges that contribute to a negative outlook on its stock. The company's immunodiagnostics and reproductive health business, which has been a major growth driver, is facing headwinds due to divestment of its China exposure and low growth in the UK. Additionally, the company's recent acquisitions of Euroimmun and BioLegend have not lived up to expectations, and there are concerns about the sustainability of the company's long-term growth projections as it faces competition and challenges in its key markets. Furthermore, Revvity's focus on signals software may not be enough to offset the challenges in its life sciences business, and downside risks such as macroeconomic conditions and M&A integration could further negatively impact the company's performance.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares